The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC).
 
Carter Norton
No Relationships to Disclose
 
Jarrod Smith
No Relationships to Disclose
 
Zach Rubnitz
No Relationships to Disclose
 
Grace H. Tan
No Relationships to Disclose
 
Christopher Duane Nevala-Plagemann
No Relationships to Disclose
 
Heloisa P. Soares
Honoraria - TM Isotope Technologies Munich SE
Consulting or Advisory Role - AstraZeneca; Ipsen; Novartis; Pfizer; TerSera
(OPTIONAL) Uncompensated Relationships - Healing NET Foundation; NCCN; North American Neuroendocrine Tumor Society
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Jazz Pharmaceuticals; Kanaph Therapeutics; OncXerna Therapeutics; SOTIO
Research Funding - Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst)
 
Vaia Florou
Consulting or Advisory Role - Deciphera; Incyte